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Abstract
Background: After the introduction of the seven valent-pneumococcal conjugated vaccine into our
National Immunization Program, it is important to establish and track local serotype distribution in order
to evaluate its impact specially because serotype replacement phenomena has been described.
To describe the clinical, epidemiological and antimicrobial resistance patterns of Costa Rican children with
otitis media caused by Streptococcus pneumoniae serotype 3.
Methods: Middle ear fluid samples were obtained from Costa Rican children with otitis media who
participated in various antimicrobial clinical trials between 1992 and 2007. Streptococcus pneumoniae was
identified according to laboratory standard procedures. Strains were serotyped and antimicrobial
susceptibility to penicillin, amoxicillin, cefuroxime, ceftriaxone, azithromycin and levofloxacin was
determined by E-test.
Results: Throughout 1992–2007 a total of 1919 tympanocentesis were performed in children with otitis
media (median age: 19 months) and yielded a total of 1208 middle ear isolates. The most common
pathogens were: Streptococcus pneumoniae, 511 isolates (49%); Non-Typable Haemophilus influenzae, 386
isolates (37%); Moraxella catarrahalis, 100 isolates (9.5%); and Streptococcus pyogenes, 54 isolates (5%).
Streptococcus pneumoniae serotyping was performed in 346/511 isolates (68%) recovered during years
1999–2006. The most common serotypes were 19F (101/30.0%), 14 (46/13.7%), 3 (34/10.1%), 6B (30/
8.9%) and 23F (23/6.8%). Analysis performed per years showed a higher prevalence of serotype 3
Streptococcus pneumoniae during the study period 2004 and 2005. During the entire study period (1999–
2006) serotype 3 was most commonly isolated in children older than 24 months (61.2% vs 40.6%;P = 0.05)
and showed a lower rate of penicillin non-susceptibility (4.0% vs 18%; P = 0.003).
Conclusion: Streptococcus pneumoniae serotype 3 is an important pathogen in Costa Rican children with
otitis media, especially in children older than 24 months of age (P = 0.05). Most serotype 3 isolates were
susceptible to penicillin, cephalosporins, macrolides and quinolones.
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Streptococcus pneumoniae (S. pneumoniae) is one of the
most common bacterial pathogens producing invasive
and non-invasive disease in healthy and immunocom-
prised hosts [1]. Invasive pneumococcal disease (IPD) can
lead to high morbidity and mortality and according to
data from the World Health Organization is the most fre-
quent cause of vaccine preventable mortality particularly
in developing countries [2].
Otitis media (OM) represents the most common non-
invasive disease caused by S. pneumoniae [1]. It has been
estimated that the overall incidence of acute otitis media
is 1.4 episodes/year/child [3]. Among these children, 20%
will develop recurrent otitis media (ROM) and 10% will
represent an otitis media therapeutic failure [3]. S. pneu-
moniae is responsible for approximately 38% of all cases
of OM worldwide and 30 to 61% of OM episodes in Latin
American children [3-5].
Recently a seven valent-pneumococcal conjugated vaccine
(PCV-7) containing serotypes 4, 6B, 9V, 14, 18C, 19F and
23F, has been introduced into the National Immuniza-
tion Programs in different parts of the world [6-9]. This
vaccine has shown to be effective in reducing pneumococ-
cal disease burden in countries where it is offered [6-9].
Unfortunately its introduction has being postponed in
developing countries where a high number of children are
at risk for non-invasive and invasive disease [9].
Following the introduction of the PCV-7 in various
regions of the world, an important decline in the number
of invasive S. pneumoniae disease [8] and a moderate
decrease in the number of OM episodes have been
reported [10-12]. Kaiser Permante Study group have
reported an efficacy of 7% reduction in the number of
acute otitis media (AOM) episodes, 22.8% reduction in
frequent otitis, and 20% reduction ventilatory tubes
placement with an overall 67% vaccine serotype otitis
media efficacy [11]. Besides, in Finland a 57% of PCV-7
vaccine efficacy against vaccine type (VT) serotypes was
found in AOM episodes and a 39% decrease in ventilator
placement was reported [10]. Zhou at al demonstrated a
42.7% and 41.9% reduction in rates of ambulatory visits
and antibiotic prescriptions associated to AOM, respec-
tively, four years after universal PCV-7 use in the United
States [13].
In spite of the PCV-7 efficacy, a serotype replacement phe-
nomenon by non-vaccine serotypes (NVT) has been
described [14,15]. Serotype 3 has been reported as one of
the most common middle ear fluid (MEF) replacement
isolates [15] and as a common cause of necrotizing pneu-
monia [16]. Furthermore, other studies have clearly indi-
cated that, when detected in the nasopharynx, serotype 3
is prone to produce OM [17] and a recent study with an
eleven-valent vaccine showed that because of the big cap-
sule, antibodies induction against this serotype is difficult
[18,19].
This study, describes the clinical, epidemiological and
antimicrobial resistance patterns of serotype 3 produced-
OM in Costa Rican children and its role in OM.
Methods
Study population
The present study was a retrospective analysis of an otitis
media data base, which includes demographic, clinical
(including vaccination records) and bacteriological infor-
mation. The study population included children with oti-
tis media who participated in different OM antimicrobial
clinical trials between 1992 and 2007 in Costa Rica, in
whom a MEF sample for bacterial culture was obtained.
All tympanocentesis were done previous to the use of anti-
biotics. None of the patients received placebo during any
of the clinical trials. For the analysis of this study, each
bacterial isolated was counted only once.
All the studies were approved by one of the following
Institutional Review Boards (IRB) or Independent Ethics
Committee (Costa Rican Social Security Institutional
Review Board; Universidad de Ciencias Médicas Ethical
Committee and CIMA Hospital Ethical Committee. Also,
for every participant written informed consent was
obtained from the parent or legal representative before
inclusion into each study.
Pneumococcal conjugated seven valent vaccine was intro-
duced in year 2004 in a limited sector of Costa Rican chil-
dren in year 2004 (10% to 20% of children). None of the
study participants have received the seven valent-pneu-
mococcal conjugated vaccine.
Definitions
The following definitions were used for the analysis of
children included in the present analysis: otitis media;
children with at least one of the following ear findings:
purulent otorrhea for less than 48 hours or at least two
otoscopic signs of middle ear effusion (decreased or
absent tympanic membrane mobility, yellow or white dis-
coloration of tympanic membrane or opacification of
tympanic membrane) and at least one indication of acute
inflammation (ear pain, marked redness of tympanic
membrane or distinct fullness or bulging of tympanic
membrane); Acute otitis media (AOM), signs and symp-
toms of otitis media for ≤ 72 h; recurrent otitis media
(ROM), history of 3 or more episodes of OM in the last 6
months or 4 or more episodes in the last 12 months
(including the current episode); and failure otitis media
(FOM), persistence of signs and symptoms of OM for 48Page 2 of 6
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sode of OM occurring within 14 days after the last dose of
an antimicrobial prescribed for an OM episode.
Middle ear fluid sampling
Tympanocentesis was performed as previously described
[4,5]. In case a participant had a perforated tympanic
membrane, removal and cleaning of the ear canal material
was done and deep aspiration of the MEF material was
attempted. MEF samples were immediately transferred to
the local research laboratory in amies medium without
charcoal (Copan diagnostics inc., Corona, ca®) for
processing.
Microbiology
Inoculation of the middle ear aspirate was performed
onto: blood agar, chocolate agar, McConkey agar and
mannitol salt agar for incubation at 35°C in a 5% CO2
environment with a relative humidity of 80–90% for 18
to 72 h at the local laboratory facilities of Centro de Inves-
tigaciones Clínicas, San José, Costa Rica. If no growth was
observed after 72 h, the culture was considered sterile. If
growth was present on solid media, identification was
performed by standard procedures [20]. For the analysis
of this study, S. pneumoniae, Non-Typable Haemophilus
influenzae (NT H. influenzae), Moraxella Catarrhalis (M.
catarrhalis) and Streptococcus pyogenes (S. pyogenes) were
considered target MEF pathogens, all other isolates were
considered as potential contaminants. All Non-Typable
H. influenzae and M. catarrhalis isolates were tested for
beta-lactamase production with the use of the cefinase
disk.
Streptococcus pneumoniae isolates serotyping
Isolates were stored at -70°C at the Centro de Investiga-
ciones Médicas in Costa Rica using Micro Bank vials (Pro-
Lab Diagnostics, Austin, TX) until shipped on dry ice or
transport medium to the Pediatric Infectious Disease
Research Laboratory at the Soroka University Medical
Center, Beer-Sheva, Israel where serotyping was per-
formed by the quellung reaction using antisera from Stat-
ens Serum Institute of Copenhagen, Denmark [20].
Serotyping was performed only in pneumococcal isolates
recovered from the middle ear between years 1999 and
2006. Strains collected before 1999 were not available for
analysis and strains from 2007 have not been serotyped
yet.
Antimicrobial susceptibility
Susceptibility testing of S. pneumoniae isolates was per-
formed for penicillin, amoxicillin, cefuroxime, ceftriax-
one, azithromycin, and levofloxacin and determined by
minimal inhibitory concentration (MIC) by means E-test
(PDM Epsilometer, AB Biodisk, Solma, Sweden). Suscep-
tibility testing and interpretation for MIC breakpoints was
done following the Clinical and Laboratory Standards
Institute (CLSI) guidelines [20]. Susceptibility tests to
penicillin were done using the cut-off for oral treatment:
MIC value of ≤ 0.06 mg/L were considered susceptible to
penicillin (PSSP); isolates with an MIC value between
0.125 and ≤ 1.0 mg/L were considered intermediate to
penicillin (PISP) and those with an MIC value ≥ 2.0 mg/L
were defined as penicillin-resistant (PRSP).
Statistical analysis
The Statistical package EPI INFO (version 6.0) was used to
test differences (by the Fisher's exact test, Yates Chi Square




Among 1919 children with otitis media, 1208 bacterial
pathogens were obtained from the MEF during the study
period (Table 1). Acute otitis media (AOM), recurrent oti-
tis media (ROM), failure otitis media (FOM) and FOM/
ROM represented 72%, 17.0%, 8.3% and 2.4% of all
cases, respectively. None of the study participants have
received the seven valent-pneumococcal conjugated vac-
cine.
The most common pathogens were S. pneumoniae, 511
isolates (42.3%); NT H. influenzae, 386 isolates (32%); M.
catarrahalis, 100 isolates (8.2%); and S. pyogenes, 54 iso-
lates (4.47%); other pathogens were isolated in 157 chil-
dren (13.0%).
Among the 511 patients where S. pneumoniae was isolated,
information regarding the type of otitis media type was
available for 460 children; S. pneumoniae was isolated in
Table 1: Total population according to different study analysis steps
STUDY POPULATION YEARS TOTAL PERCENTAGE
Tympanocentesis performed 1992–2007 1919
Bacterial pathogens isolated 1992–2007 1208/1919 62.9%
S. pneumonia positive cultures 1992–2007 511/1208 42.3%
S. pneumonia serotyping 1999–2006 346/511 68.0%Page 3 of 6
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dren, 28 (6.0%) of FOM children and in 8 children with
history of ROM and with a current FOM episode (1.7%).
Streptococcus pneumoniae characteristics
S. pneumoniae serotyping was performed in 346/511
(68%) MEF isolates recovered between 1999 and 2006; as
explained, in the remaining 32% of the pneumococcal
isolates serotyping was not performed. The most common
serotypes were 19F (101/30.0%), 14 (46/13.7%), 3 (34/
10.1%), 6B (30/8.9%), and 23F (23/6.8%). Other sero-
types represented 112 isolates (32%) (Figure 1).
Serotype 3 Streptococcus pneumoniae characteristics
S. pneumoniae serotype 3 was recovered from 34 MEF sam-
ples representing 10% of all pneumococcal isolates during
the study period; however, this serotype became more
prominent during years 2004 and 2005 as compared to
the other study years (Table 2). Ninety six percent of S.
pneumoniae serotype 3 isolates had a mucoid macroscopic
appearance
When comparing the serotype 3 isolates with the other
pneumococcal serotypes (control group), 62% of children
with serotype 3 otitis media were older than 24 months
whereas in the control group this percentage was 41% (P
= 0.05). Distribution of serotype 3 per clinical diagnosis
was: 26 (76%) AOM children; 1 (3%) FOM children and
7 (20%) ROM children and in 18 patients the disease was
bilateral. No statistical difference was found when otitis
media clinical diagnosis and laterality presentation were
compared between serotype 3 OM episodes to OM epi-
sodes by another serotype.
Antimicrobial susceptibility
Penicillin susceptibility testing was performed in 28/34
serotype 3 isolates. Ninety six percent of serotype 3 iso-
lates (27/28) were penicillin susceptible isolates (PSSP)
and one was intermediate; however, only 79% (239/303)
of other S. pneumoniae serotypes were penicillin suscepti-
ble (P = 0.003).
All S. pneumoniae isolates where fully susceptible to other
antibiotics: amoxicillin, cefuroxime, ceftriaxone, faro-
penem, azithromycin and levofloxacin.
Clinical Outcome
Per the different study protocols, no statistical difference
was found in the clinical and bacteriological outcome at
the end of treatment (days 11–14) and at the end of study
visit (days 28–32) among patients with OM caused by
serotype 3 compared to the clinical and bacteriological
outcome observed in patients with OM with other sero-
types.
Eighty-nine percent (26/29) of patients from whom S.
pneumoniae serotype 3 was isolated were cured or
improved at the end of treatment visit 82.7% (24/29)
remained cured at the end of study visit. Similarly, among
children in whom another MEF pneumococcal, the per-
centage of children cured was 85.5% (186/218) and
79.8% (174/218) remained cured at the end of study visit.
Discussion
Otitis media represents one of the principal causes for
medical consultation and antibiotic prescription in the
pediatric population. It has been estimated that in the
USA this disease is responsible for approximately 30 mil-
lion outpatient visits per year, representing an economic
impact of more than 2 billion dollars per year [3].
S. pneumoniae is the most common pathogen producing
OM in children worldwide [3]. To date, > 90 pneumococ-
cal serotypes have been reported [1]. Because the intro-
duction of PCV7 has been associated with a serotype
replacement phenomenon in some countries [14,15], it is
important to perform regular serotype analysis surveil-
lance among children with OM to predict the potential
impact of the vaccine and establish serotype natural
dynamics.
This study analyzed the serotype distribution of S. pneu-
moniae recovered from the MEF of Costa Rican children
Serotype distribution among 346 Streptococcus pneumoniae isola es from Costa Rican children with otitis media 1999–2006Figure 1
Serotype distribution among 346 Streptococcus pneu-
moniae isolates from Costa Rican children with otitis 
media 1999–2006.Page 4 of 6
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was recovered from 34 MEF samples representing 10% of
all pneumococcal isolates between 1999 and 2006 with
the typical yearly fluctuation characteristics, becoming
particularly common among Costa Rican Children during
years 2004, 2005 and less common during 2006. These
serotype yearly fluctuations are particularly important.
However, these results must be interpreted with caution
because only 68% of all S. pneumoniae isolates were sero-
typed, serotype 3 representing 6.7% of all neumococcal
isolates serotyped, which can introduce a biass to the data
analysis. In spite of this, when analyzing serotype 3 fre-
quency among the study years, there was a yearly fluctua-
tion and represent the foundations for a continues
surveillance even after the vaccine is introduce in a specific
region.
Although in only 63% of the patients a bacterial isolated
was recovered, the use of antibiotics as part of the clinical
trials didn't influences the results due to the tympanocen-
tesis was performed previous to the antibiotic use.
The introduction of the seven valent conjugated pneumo-
coccal vaccine in the USA has shown to be very effective
decreasing the incidence of invasive pneumococcal dis-
ease in children. However, new non-vaccine serotypes,
such as serotype 3, have emerged as cause of disease [15].
This is particularly important because creating a vaccine
that elicits appropriate and effective antibodies against
serotype 3 may be difficult because of the large size cap-
sule this serotype exhibits. Even more, a recent trial with
an eleven valent vaccine that contained antigens for sero-
type 3 failed to elicit good antibody levels [18,19]. A 13
valent vaccine with antigens for serotype 3 is under con-
sideration by different regulatory agencies but still is not
yet available.
Similar to previous studies, our results also show that sixty
percent of children with OM due to S. pneumoniae sero-
type 3 were older than 24 months at diagnosis and 96%
of the isolates had a macroscopic mucoid appearance. The
presence of this mucoide apperance could be an impor-
tant virulence factor which could limit the effectiveness of
the pneumococcal vaccine for otitis media [21].
Antimicrobial susceptibility results demonstrated that
94% of serotype 3 isolates were PSSP but only 79% of
other serotypes were PSSP. There was no susceptibility dif-
ferences with the other antibiotics tested. This finding sug-
gests that, although serotype 3 has increased as major OM
pathogen in Costa Rican children > 24 months of age,
common antimicrobial agents such as amoxicillin should
be considered the first therapeutic option to treat these
patients.
Conclusion
In conclusion S. pneumoniae serotype 3 has increased as
otitis media pathogen in Costa Rican children with OM;
this should be considered when introducing any future
pneumococcal vaccine in the National Vaccines Programs.
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